Vincent J. Angotti - Feb 10, 2023 Form 4 Insider Report for ACELRX PHARMACEUTICALS INC (ACRX)

Role
Chief Executive Officer, Director
Signature
/s/ Martha Adler, Attorney-In-Fact
Stock symbol
ACRX
Transactions as of
Feb 10, 2023
Transactions value $
-$5,579
Form type
4
Date filed
2/14/2023, 03:19 PM
Previous filing
Feb 8, 2023
Next filing
Mar 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRX Common Stock Award $0 +19.5K +39.51% $0.00 68.9K Feb 10, 2023 Direct F1, F2
transaction ACRX Common Stock Tax liability -$5.58K -3.32K -4.82% $1.68 65.5K Feb 11, 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRX Stock Option (Right to Buy) Award $0 +117K $0.00 117K Feb 10, 2023 Common Stock 117K $1.76 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units shall vest in three equal consecutive annual installments on February 10, 2024, February 10, 2025 and February 10, 2026.
F2 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F3 Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
F4 On February 10, 2023, the reporting person was granted an option to purchase 117,000 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods.